Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
CD47 encodes a membrane protein, which is involved in the increase in intracellular calcium concentration that occurs upon cell adhesion to extracellular matrix.
Showing 4 out of 14 products:
Our results support an intrinsic role of CD47 in ovarian cancer progression and immune evasion
Mechanistic studies suggest a PKC (show PKC ELISA Kits)-Syk (show SYK ELISA Kits)-mediated signaling pathway, to which IL-10 (show IL10 ELISA Kits) conversely inhibits, is required for activating macrophage self-targeting, followed by phagocytosis independent of calreticulin (show CALR ELISA Kits) Moreover, we identified spleen red pulp to be one specific tissue that provides stimuli constantly activating macrophage phagocytosis albeit lacking in Cd47(-/-) or Sirpalpha(-/-) mice.
mice deficient in CD47 (CD47 Knockout) had significantly less brain neutrophil infiltration at 24h, upregulated VEGF (show VEGFA ELISA Kits) expression in peri (show POSTN ELISA Kits)-lesion cortex at 7 and 14day
TSP1 (show GZMA ELISA Kits) significantly accelerates replicative senescence and associated cell cycle arrest in a CD47-dependent manner.
CD47, TSP1 (show GZMA ELISA Kits), and to a lesser extent SIRPalpha facilitate exosome-mediated myeloid-derived suppressor cells chemotaxis and migration.
In pulmonary hypertension TSP1 (show GZMA ELISA Kits)-CD47 is upregulated, and contributes to pulmonary arterial vasculopathy and dysfunction.
thrombospondin-1 (show THBS1 ELISA Kits) via CD47 inhibits renal tubular epithelial cell recovery after ischemia reperfusion injury through inhibition of proliferation/self-renewal.
these findings have demonstrated how tumor cells inhibit innate sensing in dendritic cells and suggested that the CD47-SIRPalpha axis is critical for dendritic cell-driven antitumor immunity
this study shows that CD47 deficiency in tumor stroma promotes tumor progression by enhancing angiogenesis
the results obtained by combining bioinformatics and preclinical studies strongly suggest that targeting TSP-1 (show GZMA ELISA Kits)/CD47 axis may represent a valuable therapeutic alternative for hampering melanoma spreading.
CD47 expression is decreased on the surface of erythrocytes in obese subjects. These changes in CD47 expression on the erythrocytes surface may be an adaptive response to hyperfibrinogenemia associated with obesity.
Results show that the thrombospondin 1 (TSP1 (show THBS1 ELISA Kits)) and its receptor CD47 (CD47) axis selectively regulates NADPH oxidase 1 (Nox1 (show NOX1 ELISA Kits)) in the regulation of endothelial senescence and suggest potential targets for controlling the aging process at the molecular level.
CD47 is overexpressed in primary non-small cell lung cancer (NSCLC) tissues and cell lines, suggesting that CD47 is a promising therapeutic target for NSCLC.
Among the various candidate genes involved in acute rejection, CD47 inhibits monocyte/macrophage-mediated phagocytosis by identifying the CD47 signal regulatory protein alpha (SIRP (show SIRPA ELISA Kits)-alpha) as self/non-self. Tissue factor pathway inhibitor (TFPI (show TFPI ELISA Kits)) is involved in the regulation of the coagulation pathway and is able to bind to another ligand of CD47, thrombospondin-1 (TSP-1 (show THBS1 ELISA Kits)).
Blocking CD47 using antibodies could efficiently induce macrophage-mediated phagocytosis of tumor cells and treat cancers.
High CD47 expression is not associated with Fibrolamellar Hepatocellular Carcinoma.
TTI-621 (SIRPalphaFc) is a fully human recombinant fusion protein that blocks the CD47-SIRPalpha axis by binding to human CD47 and enhancing phagocytosis of malignant cells..These data indicate that TTI-621 is active across a broad range of human tumors.
this review highlights the various functions of CD47, discusses anti-tumor responses generated by both the innate and adaptive immune systems as a consequence of administering anti-CD47 blocking antibody, and finally elaborates on the clinical potential of CD47 blockade.
we observed neutrophilic infiltration was slightly increased in anti-CD47 treated tumors compared to IgG control.
In pulmonary hypertension TSP1 (show THBS1 ELISA Kits)-CD47 is upregulated, and contributes to pulmonary arterial vasculopathy and dysfunction.
Amyloid-beta inhibits No-cGMP signaling in a CD36 (show CD36 ELISA Kits)- and CD47-dependent manner
Genetic induction of human CD47 on porcine cells could provide inhibitory signaling to SIRPalpha on human macrophages, providing a novel approach to preventing macrophage-mediated xenograft rejection.
This gene encodes a membrane protein, which is involved in the increase in intracellular calcium concentration that occurs upon cell adhesion to extracellular matrix. The encoded protein is also a receptor for the C-terminal cell binding domain of thrombospondin, and it may play a role in membrane transport and signal transduction. This gene has broad tissue distribution, and is reduced in expression on Rh erythrocytes. Alternatively spliced transcript variants have been found for this gene.
, integrin-associated protein
, leukocyte surface antigen CD47
, CD47 antigen (Rh-related antigen, integrin-associated signal transducer)
, CD47 glycoprotein
, antigen identified by monoclonal antibody 1D8
, antigenic surface determinant protein OA3
, integrin associated protein
, integrin-associated signal transducer
, CD47 antigen